Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 8;6(8):e00146.
doi: 10.14309/crj.0000000000000146. eCollection 2019 Aug.

Pleural Carcinosis of a Cholangiocarcinoma

Tomasz Dziodzio  1 , Maximilian Jara  1 , Paul Viktor Ritschl  1 , Florian Roßner  2 , Robert Öllinger  1 , Johann Pratschke  1 , Jens Neudecker  1
Affiliations

Pleural Carcinosis of a Cholangiocarcinoma

Tomasz Dziodzio et al. ACG Case Rep J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Computed tomography of pulmonary nodules and pleural carcinosis with malignant pleura effusion.
Figure 2.
Figure 2.
Intraoperative picture of pleural carcinosis showing a brown affection covered with white nodules.
Figure 3.
Figure 3.
Histological examination of the pleural and the pulmonary nodule biopsies showing desmoplastic stromas with tubular, papillotubular, and cribriform patterns and medium-sized cuboidal to columnar cells, corresponding to metastases of a moderately differentiated cholangiocarcinoma. (A) Hematoxylin and eosin stain. (B) Expression of CK7. (C) KI-67 proliferation rate of 30% (MIB-1).
See this image and copyright information in PMC

References

    1. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–5; discussion 473–75. - PMC - PubMed
    1. Groot Koerkamp B, Wiggers JK, Allen PJ, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221(6):1041–9. - PMC - PubMed
    1. Choi SB, Han HJ, Park PJ, et al. Disease recurrence patterns and analysis of clinicopathological prognostic factors for recurrence after resection for distal bile duct cancer. Am Surg. 2015;81(3):289–96. - PubMed
    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. - PubMed
    1. Sahu S, Sun W. Targeted therapy in biliary tract cancers-current limitations and potentials in the future. J Gastrointest Oncol. 2017;8(2):324–36. - PMC - PubMed